Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Ovarian cancer Clinical Trials

Protocol Number Title
2006LS032
MT2005-21 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
2006NT001
WCC 60 Biomarker with Biological Function in Ovarian Carcinoma/Diagnostic Markers for Ovarian Cancer: Detection of Novel Cell Adhesion Proteins in Patients' Specimens
2011NTLS041
Molecular Epidemiology of Pediatric Germ Cell Tumors
2011NTLS157
Use of Pap test samples to study human diseases
2013NTLS041
A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy
2013NTLS073
Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients: A Randomized Controlled Trial
2014IS090
APS001F-001 ? A Phase I/II safety, pharmacokinetic, and pharmacodynamic study of APS001F with flucytosine and maltose for the treatment of advanced and/or metastatic solid tumors.
2014IS121
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
2014NTLS003
Identification of Changes in Gene Expression of Epithelial Ovarian Cancer Tumors after Neoadjuvant Chemotherapy: Application of RNA-Seq Transcriptome Analysis, a Pilot Study
2014NTLS004
Mobile Phone Technology to Increase Genetic Counseling for Women with Ovarian Cancer and Their Families
2014NTLS069
Personalized mouse models of chemotherapy resistance in ovarian cancer
2016CG020
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
2016IS065
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
2016IS170
Phase II Study of Four Concentrations of Intraperitoneal NanoPac? plus Six Cycles of IV Carboplatin and Paclitaxel in Patients with Platinum-Sensitive Recurrent Stage III Epithelial Ovarian Cancer Undergoing Second Cytoreductive Surgery
2016LS034
Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only after 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
2016NTLS071
Risk Factors of 'Chemo Brain' among Women Treated for Ovarian Cancer
2016NTLS151
Cytomegalovirus Status and Adaptive Natural Killer Cells in Ovarian Cancer: A Pilot Study
2016NTLS163
Development Of A Clinical Precision Medicine Program In Ovarian Cancer As A Paradigm For 21st Century Tailored-Health Care Solutions
EAY131-Z1C
EAY131-Z1C: MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1I
EAY131-Z1I: MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations

20 trials displayed